Imunon, Inc. (0HUZ.L)

USD 0.83

(-0.97%)

Total Liabilities Summary of Imunon, Inc.

  • Imunon, Inc.'s latest annual total liabilities in 2023 was 8.53 Million USD , down -41.76% from previous year.
  • Imunon, Inc.'s latest quarterly total liabilities in 2024 Q1 was 5.82 Million USD , down -31.71% from previous quarter.
  • Imunon, Inc. reported annual total liabilities of 14.64 Million USD in 2022, down -19.74% from previous year.
  • Imunon, Inc. reported annual total liabilities of 18.25 Million USD in 2021, down -3.52% from previous year.
  • Imunon, Inc. reported quarterly total liabilities of 5.95 Million USD for 2024 Q2, up 2.15% from previous quarter.
  • Imunon, Inc. reported quarterly total liabilities of 8.53 Million USD for 2023 FY, down -41.76% from previous quarter.

Annual Total Liabilities Chart of Imunon, Inc. (2023 - 2012)

Historical Annual Total Liabilities of Imunon, Inc. (2023 - 2012)

Year Total Liabilities Total Liabilities Growth
2023 8.53 Million USD -41.76%
2022 14.64 Million USD -19.74%
2021 18.25 Million USD -3.52%
2020 18.91 Million USD -20.25%
2019 23.71 Million USD -8.75%
2018 25.99 Million USD 24.91%
2017 20.8 Million USD -13.74%
2016 24.12 Million USD -15.78%
2015 28.64 Million USD -15.43%
2014 33.86 Million USD 139.41%
2013 14.14 Million USD 5.6%
2012 13.39 Million USD 0.0%

Peer Total Liabilities Comparison of Imunon, Inc.

Name Total Liabilities Total Liabilities Difference
Editas Medicine, Inc. 150.05 Million USD 94.315%
Dynavax Technologies Corporation 375.02 Million USD 97.725%
Supernus Pharmaceuticals, Inc. 487.46 Million USD 98.25%
Perrigo Company plc 6.04 Billion USD 99.859%
Illumina, Inc. 4.36 Billion USD 99.805%
Thermo Fisher Scientific Inc. 51.88 Billion USD 99.984%
Iovance Biotherapeutics, Inc. 195.73 Million USD 95.642%
Walgreens Boots Alliance, Inc. 68.85 Billion USD 99.988%
IQVIA Holdings Inc. 20.56 Billion USD 99.959%
Heron Therapeutics, Inc. 256.47 Million USD 96.674%
Regeneron Pharmaceuticals, Inc. 7.1 Billion USD 99.88%
Unity Biotechnology, Inc. 37.29 Million USD 77.125%
Waters Corporation 3.47 Billion USD 99.755%
Biogen Inc. 12.04 Billion USD 99.929%
Sangamo Therapeutics, Inc. 82.43 Million USD 89.652%
Evolus, Inc. 209.68 Million USD 95.932%
Adicet Bio, Inc. 37.12 Million USD 77.019%
Cara Therapeutics, Inc. 68.75 Million USD 87.594%
bluebird bio, Inc. 424.62 Million USD 97.991%
Esperion Therapeutics, Inc. 660.79 Million USD 98.709%
FibroGen, Inc. 585.72 Million USD 98.544%
Agilent Technologies, Inc. 4.91 Billion USD 99.827%
Corbus Pharmaceuticals Holdings, Inc. 35.17 Million USD 75.75%
Homology Medicines, Inc. 118.53 Million USD 92.803%
Geron Corporation 146.12 Million USD 94.162%
Alnylam Pharmaceuticals, Inc. 4.05 Billion USD 99.789%
Amicus Therapeutics, Inc. 617.7 Million USD 98.619%
Myriad Genetics, Inc. 312.9 Million USD 97.274%
Viking Therapeutics, Inc. 20.07 Million USD 57.499%
Intellia Therapeutics, Inc. 250.8 Million USD 96.599%
Zoetis Inc. 9.29 Billion USD 99.908%
Abeona Therapeutics Inc. 49.17 Million USD 82.653%
Mettler-Toledo International Inc. 3.5 Billion USD 99.757%
BioMarin Pharmaceutical Inc. 1.89 Billion USD 99.549%
Vertex Pharmaceuticals Incorporated 5.14 Billion USD 99.834%
Kala Pharmaceuticals, Inc. 48.44 Million USD 82.392%
Ionis Pharmaceuticals, Inc. 2.6 Billion USD 99.672%
Atara Biotherapeutics, Inc. 264.73 Million USD 96.778%
Verastem, Inc. 71.18 Million USD 88.017%
Nektar Therapeutics 267.04 Million USD 96.806%
Axsome Therapeutics, Inc. 397.25 Million USD 97.853%
Aclaris Therapeutics, Inc. 40.22 Million USD 78.794%
Sarepta Therapeutics, Inc. 2.4 Billion USD 99.645%
OPKO Health, Inc. 622.47 Million USD 98.63%
Exelixis, Inc. 678.44 Million USD 98.743%
Neurocrine Biosciences, Inc. 1.01 Billion USD 99.163%
Corcept Therapeutics Incorporated 114.81 Million USD 92.57%
Anavex Life Sciences Corp. 12.53 Million USD 31.942%
uniQure N.V. 624.01 Million USD 98.633%
Blueprint Medicines Corporation 918.64 Million USD 99.071%
Insmed Incorporated 1.66 Billion USD 99.487%
Halozyme Therapeutics, Inc. 1.64 Billion USD 99.483%
Agios Pharmaceuticals, Inc. 126.09 Million USD 93.235%
TG Therapeutics, Inc. 169.08 Million USD 94.955%
Incyte Corporation 1.59 Billion USD 99.464%
Emergent BioSolutions Inc. 1.18 Billion USD 99.28%